Skip to main content

ASH 2016 - Multiple Myeloma

Conference Correspondent, ASH 2016 - Multiple Myeloma
PREAMBLE: Real-World Efficacy Analyses in Multiple Myeloma Patients with One Line of Prior Therapy
Read More
Conference Correspondent, ASH 2016 - Multiple Myeloma
Retreatment with Daratumumab and Pomalidomide Among Refractory Patients with Multiple Myeloma
Read More
Conference Correspondent, ASH 2016 - Multiple Myeloma
Pembrolizumab in Combination with Pomalidomide and Dexamethasone for Relapsed/Refractory Multiple Myeloma
Read More
Conference Correspondent, ASH 2016 - Multiple Myeloma
A New Risk Stratification Tool to Estimate Survival in Patients with Multiple Myeloma After First Relapse
Read More
Conference Correspondent, ASH 2016 - Multiple Myeloma
Budget Impact Analysis of Elotuzumab in Combination with Lenalidomide and Dexamethasone for Relapsed/Refractory Multiple Myeloma
Read More
Conference Correspondent, ASH 2016 - Multiple Myeloma
Phase II Study of Lenalidomide, Subcutaneous Bortezomib, and Dexamethasone (RsqVD) in Newly Diagnosed Multiple Myeloma
Read More
Conference Correspondent, ASH 2016 - Multiple Myeloma
Meta-Analysis to Compare Efficacy of Treatment Regimens for Relapsed/Refractory Multiple Myeloma Patients
Read More
Conference Correspondent, ASH 2016 - Multiple Myeloma
Real-World Trends in Treatment Use, Healthcare Costs, and Overall Survival Among Patients with Multiple Myeloma
Read More
Conference Correspondent, ASH 2016 - Multiple Myeloma
Pomalidomide and Low-Dose Dexamethasone Following Second-Line Lenalidomide-Based Therapy in Relapsed or Refractory Multiple Myeloma
Read More
Page 2 of 2
Results 11 - 19 of 19